FDA expands use of Xgeva to include giant cell tumor of the bone

06/14/2013 | Medscape (free registration)

The FDA approved the use of Amgen's Xgeva, or denosumab, to treat adults and some adolescents with giant cell tumor of the bone when surgery is not an option. The decision makes denosumab the first approved drug for this condition. Xgeva, a fully human monoclonal antibody, was previously approved for treatment of osteoporosis and for prevention of skeletal-related events in adults with bone metastases and solid tumors.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA